Does prophylactic N acetylcysteine reduce the incidence of contrast nephropathy in patients undergoing peripheral angiography - NAC as a Nehroprotective agent in Peripheral Angiography

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2005-005809-38-GB

Enrollment

Registered

2006-01-10

Start date

2006-12-08

Completion date

Unknown

Last updated

2019-06-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

We will use N acetylcystiene prophylactically in patient undergoing peripheral angiography at the Cambridge Vascular Unit at Addenbrooke's Hospital in order to prevent renal injury. Patients undergoing peripheral angiography have large quanities of contrast medium injected intravenously, contrast medium is a nephrotoxic substance. Thge drug will be administrated prophylactically to aviod acute renal failure.

Interventions

Trade Name: Fluimucil Pharmaceutical Form: Effervescent tablet INN or Proposed INN: N acetylcysteine Concentration unit: mg/kg milligram(s)/kilogram

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Any patient undergoing peripheral angiography in the Cambridge Vascular Unit, Addenbrooke’s Hospital, Cambridge who consents to participation Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Any patient undergoing peripheral angiography in Cambridge Vascular Unit, Any patient that does not consent to participation in the study. Any patient under the age of 18 years Any patient with established renal failure on renal replacement therapy (dialysis).

Design outcomes

Primary

Measure	Time frame
Main Objective: To investigate the role of N acetylcysteine as a nephroprotective agent in patients undergoing peripheral angiography at Addenbrooke’s Hospital, Cambridge. Primarily we are looking for a reduction in the elevation of serum creatinine and also of other markers of renal damage in urine (retinol binding protein and albumin) A reduction in the mortality and morbidity related to renal failure that may result from a contrast medium induced nephropathy. ;Secondary Objective: ;Primary end point(s): To obtain eveidence that shows prophylactic use of N acetylcysteine is significantly nephroprotective for patients undergoing peripheral angiography	—

Measure

Time frame

Main Objective: To investigate the role of N acetylcysteine as a nephroprotective agent in patients undergoing peripheral angiography at Addenbrooke’s Hospital, Cambridge. Primarily we are looking for a reduction in the elevation of serum creatinine and also of other markers of renal damage in urine (retinol binding protein and albumin) A reduction in the mortality and morbidity related to renal failure that may result from a contrast medium induced nephropathy. ;Secondary Objective: ;Primary end point(s): To obtain eveidence that shows prophylactic use of N acetylcysteine is significantly nephroprotective for patients undergoing peripheral angiography

—

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026